医学
人类免疫缺陷病毒(HIV)
西达
内科学
慢病毒
免疫病理学
病毒性疾病
重症监护医学
临床试验
梅德林
抗逆转录病毒疗法
免疫学
病毒载量
年轻人
病毒学
人口
肿瘤科
化疗
逆转录酶抑制剂
风险因素
作者
Debbie P. Hagins,Mezgebe Berhe,Gordon E. Crofoot,Moti N. Ramgopal,James Sims,Cheryl McDonald,Peter Jerome Ruane,William E. Sanchez,Anita Scribner,Paul M. Benson,Shanyu Liu,Laurie A. VanderVeen,Hadas Dvory‐Sobol,Martin S. Rhee,Samir Kumar Gupta
出处
期刊:AIDS
[Lippincott Williams & Wilkins]
日期:2025-10-06
卷期号:40 (3): 302-311
被引量:9
标识
DOI:10.1097/qad.0000000000004372
摘要
OBJECTIVE: To assess final efficacy (through Week [W] 132), safety, and emergent resistance with lenacapavir-based combination regimens in the CALIBRATE study. DESIGN: CALIBRATE was a Phase 2, randomized, open-label study (NCT04143594). METHODS: Treatment-naive PWH were randomized (2 : 2:2 : 1) to four treatment groups (TG): TG1 and TG2 received twice-yearly subcutaneous lenacapavir plus oral daily emtricitabine/tenofovir alafenamide (F/TAF); TG3 received oral daily lenacapavir plus F/TAF; and TG4 received oral daily bictegravir/F/TAF. At W28, TG1 switched to lenacapavir plus TAF and TG2 switched to lenacapavir plus bictegravir. At W80, TG4 completed the study and TG1-3 continued assigned treatments. RESULTS: Overall, 182 participants received at least one dose of study drug (TG1-4, respectively: n = 52, n = 53, n = 52, n = 25). Virologic suppression (HIV-1 RNA <50 copies/ml) at W80 by FDA snapshot: 87, 75, 87, and 92% in TG1-4, respectively. When excluding missing data, virologic suppression at W132 across TG1-3 was 98-100%. Mean (95% CI) increase from baseline to W80 in CD4 cells/μl was consistent across TG1-4: 275 (214; 337), 262 (203; 320), 245 (174; 315), and 248 (155; 340), respectively. No serious treatment-related adverse events occurred. Two participants in TG1 and three in TG2 discontinued study drug due to adverse events. Injection-site reactions were mostly mild to moderate. LEN resistance-associated mutations emerged in four participants. CONCLUSION: Lenacapavir-containing combinations achieved and maintained high rates of virologic suppression in treatment-naive participants through W132; lenacapavir was well tolerated. These data support future development of lenacapavir-containing regimens for HIV-1 treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI